388566-97-0
Chemical Structure
APL180
Synonym(s): L-4F
- CAS No.: 388566-97-0
- Formula:C114H156N24O28
- Molecular Weight:2310.60
InChIKey: ZKKBZMXTFBAQLP-AAPMWPAESA-N
SMILES: O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(C)C)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@H](C(N)=O)CC1=CC=CC=C1)=O)C)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)CC3=CC=C(O)C=C3)=O)CC4=CC=CC=C4)=O)C)=O)=O)CC5=CC=CC=C5)=O)CC6=CNC7=C6C=CC=C7)=O)CC(O)=O)C
Biological Activity: APL180 (L-4F) is an Apo-A1 mimetic peptide. APL180 binds oxidized/oxidizable lipids with high affinity and sequesters pro-inflammatory oxidized lipids. APL180 downregulates glycolysis-related genes and HIF-1α expression, and upregulates CD206 and Arginase. APL180 inhibits atherosclerotic lesion progression and platelet aggregation. APL180 attenuates adverse left ventricular remodeling and systolic dysfunction after myocardial infarction. APL180 can be used for research on ovarian cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
APL180 | APL180 (L-4F) is an Apo-A1 mimetic peptide. APL180 binds oxidized/oxidizable lipids with high affinity and sequesters pro-inflammatory oxidized lipids. APL180 downregulates glycolysis-related genes and HIF-1α expression, and upregulates CD206 and Arginase. APL180 inhibits atherosclerotic lesion progression and platelet aggregation. APL180 attenuates adverse left ventricular remodeling and systolic dysfunction after myocardial infarction. APL180 can be used for research on ovarian cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Watson CE, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011 Feb;52(2):361-73. . [Content Brief]
- [2]. Hamid T, et al. The apolipoprotein AI mimetic L-4F attenuates monocyte activation and adverse cardiac remodeling after myocardial infarction. International journal of molecular sciences. 2020 May 15;21(10):3519.
- [3]. López-Valencia L, et al. ApoAI-LPS aggregates are found in the frontal cortex of female rats after alcohol binge drinking: effects of ApoAI mimetic peptide on behaviour. IBRO Neuroscience Reports. 2023 Oct 1;15:S862.
